摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-[3-(4-氯苯基)-1,2,4-恶二唑-5-基]乙胺 | 915921-14-1

中文名称
1-[3-(4-氯苯基)-1,2,4-恶二唑-5-基]乙胺
中文别名
——
英文名称
1-(3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl)ethanamine
英文别名
1-[3-(4-Chlorophenyl)-1,2,4-oxadiazol-5-YL]ethanamine
1-[3-(4-氯苯基)-1,2,4-恶二唑-5-基]乙胺化学式
CAS
915921-14-1
化学式
C10H10ClN3O
mdl
MFCD08691835
分子量
223.662
InChiKey
HNDBFFBSXOAWPV-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    355.1±52.0 °C(Predicted)
  • 密度:
    1.291±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.7
  • 重原子数:
    15
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.2
  • 拓扑面积:
    64.9
  • 氢给体数:
    1
  • 氢受体数:
    4

安全信息

  • 海关编码:
    2934999090

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH<br/>[FR] 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES COMME INHIBITEURS D'IDH MUTANTE
    申请人:NOVARTIS AG
    公开号:WO2014141104A1
    公开(公告)日:2014-09-18
    The invention is directed to a formula (I), or a pharmamceutically acceptable salt thereof, wherein R1, R2a, R2b and R3-R7 are herein. The invention is also directed to compositions containing a compound of formula (I) and to the use of such compounds in the inhibition of mutant IDH proteins having a neomorphic activity. The invention is further directed to the use of a compound of formula (I) in the treatment of diseases or disorders associated with such mutant IDH proteins including, but not limited to, cell-proliferation disorders, such as cancer.
    这项发明涉及一种式(I)的配方,或其药用可接受的盐,其中R1、R2a、R2b和R3-R7在此处。该发明还涉及含有式(I)化合物的组合物,以及在抑制具有新型活性的突变IDH蛋白中使用这种化合物的用途。该发明还涉及在治疗与这种突变IDH蛋白相关的疾病或紊乱中使用式(I)化合物,包括但不限于细胞增殖紊乱,如癌症。
  • 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH
    申请人:VESTAS WIND SYSTEMS A/S
    公开号:US20140235620A1
    公开(公告)日:2014-08-21
    The invention is directed to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R 1 -R 6 are defined herein. The invention is also directed to compositions containing a compound of formula (I) and to the use of such compounds in the inhibition of mutant IDH proteins having a neomorphic activity. The invention is further directed to the use of a compound of formula (I) in the treatment of diseases or disorders associated with such mutant IDH proteins including, but not limited to, cell-proliferation disorders, such as cancer.
    该发明涉及公式(I)的化合物或其药用盐,其中R1-R6在此处定义。该发明还涉及含有公式(I)化合物的组合物,以及利用这些化合物抑制具有新型活性的突变IDH蛋白。该发明还涉及利用公式(I)的化合物治疗与这些突变IDH蛋白相关的疾病或紊乱,包括但不限于细胞增殖紊乱,如癌症。
  • 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH
    申请人:Caferro Thomas Raymond
    公开号:US08957068B2
    公开(公告)日:2015-02-17
    The invention is directed to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R1-R6 are defined herein. The invention is also directed to compositions containing a compound of formula (I) and to the use of such compounds in the inhibition of mutant IDH proteins having a neomorphic activity. The invention is further directed to the use of a compound of formula (I) in the treatment of diseases or disorders associated with such mutant IDH proteins including, but not limited to, cell-proliferation disorders, such as cancer.
    本发明涉及式(I)的化合物或其药学上可接受的盐,其中R1-R6在此定义。本发明还涉及含有式(I)的化合物的组合物,并且涉及使用这种化合物来抑制具有新型活性的突变IDH蛋白质。本发明还涉及使用式(I)的化合物来治疗与这种突变IDH蛋白质相关的疾病或紊乱,包括但不限于细胞增殖紊乱,如癌症。
  • 3-(PYRIMIDIN-4-YL)-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH
    申请人:Novartis AG
    公开号:EP2771337B1
    公开(公告)日:2017-08-02
  • US20140275083A1
    申请人:——
    公开号:US20140275083A1
    公开(公告)日:2014-09-18
查看更多